vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and ALBANY INTERNATIONAL CORP (AIN). Click either name above to swap in a different company.
ALBANY INTERNATIONAL CORP is the larger business by last-quarter revenue ($321.2M vs $284.0M, roughly 1.1× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 4.3%, a 92.0% gap on every dollar of revenue. On growth, ALBANY INTERNATIONAL CORP posted the faster year-over-year revenue change (12.0% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 1.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
ACAD vs AIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $321.2M |
| Net Profit | $273.6M | $13.9M |
| Gross Margin | 90.8% | 31.1% |
| Operating Margin | 6.1% | 9.3% |
| Net Margin | 96.3% | 4.3% |
| Revenue YoY | 9.4% | 12.0% |
| Net Profit YoY | 90.3% | -21.5% |
| EPS (diluted) | $1.61 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $321.2M | ||
| Q3 25 | $278.6M | $261.4M | ||
| Q2 25 | $264.6M | $311.4M | ||
| Q1 25 | $244.3M | $288.8M | ||
| Q4 24 | $259.6M | $286.9M | ||
| Q3 24 | $250.4M | $298.4M | ||
| Q2 24 | $242.0M | $332.0M | ||
| Q1 24 | $205.8M | $313.3M |
| Q4 25 | $273.6M | $13.9M | ||
| Q3 25 | $71.8M | $-97.8M | ||
| Q2 25 | $26.7M | $9.2M | ||
| Q1 25 | $19.0M | $17.4M | ||
| Q4 24 | $143.7M | $17.7M | ||
| Q3 24 | $32.8M | $18.0M | ||
| Q2 24 | $33.4M | $24.6M | ||
| Q1 24 | $16.6M | $27.3M |
| Q4 25 | 90.8% | 31.1% | ||
| Q3 25 | 92.2% | -19.1% | ||
| Q2 25 | 92.2% | 31.3% | ||
| Q1 25 | 91.7% | 33.4% | ||
| Q4 24 | 91.6% | 31.5% | ||
| Q3 24 | 92.5% | 30.3% | ||
| Q2 24 | 92.5% | 33.9% | ||
| Q1 24 | 88.8% | 34.7% |
| Q4 25 | 6.1% | 9.3% | ||
| Q3 25 | 12.8% | -44.6% | ||
| Q2 25 | 12.2% | 7.2% | ||
| Q1 25 | 7.9% | 9.8% | ||
| Q4 24 | 59.1% | 8.5% | ||
| Q3 24 | 12.6% | 8.4% | ||
| Q2 24 | 12.6% | 12.9% | ||
| Q1 24 | 7.4% | 12.4% |
| Q4 25 | 96.3% | 4.3% | ||
| Q3 25 | 25.8% | -37.4% | ||
| Q2 25 | 10.1% | 2.9% | ||
| Q1 25 | 7.8% | 6.0% | ||
| Q4 24 | 55.4% | 6.2% | ||
| Q3 24 | 13.1% | 6.0% | ||
| Q2 24 | 13.8% | 7.4% | ||
| Q1 24 | 8.0% | 8.7% |
| Q4 25 | $1.61 | $0.56 | ||
| Q3 25 | $0.42 | $-3.37 | ||
| Q2 25 | $0.16 | $0.31 | ||
| Q1 25 | $0.11 | $0.56 | ||
| Q4 24 | $0.86 | $0.57 | ||
| Q3 24 | $0.20 | $0.57 | ||
| Q2 24 | $0.20 | $0.79 | ||
| Q1 24 | $0.10 | $0.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $112.3M |
| Total DebtLower is stronger | — | $455.7M |
| Stockholders' EquityBook value | $1.2B | $726.2M |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | — | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $112.3M | ||
| Q3 25 | $258.0M | $108.3M | ||
| Q2 25 | $253.6M | $106.7M | ||
| Q1 25 | $217.7M | $119.4M | ||
| Q4 24 | $319.6M | $115.3M | ||
| Q3 24 | $155.1M | $127.2M | ||
| Q2 24 | $177.1M | $116.4M | ||
| Q1 24 | $204.7M | $125.4M |
| Q4 25 | — | $455.7M | ||
| Q3 25 | — | $480.6M | ||
| Q2 25 | — | $444.7M | ||
| Q1 25 | — | $416.4M | ||
| Q4 24 | — | $318.5M | ||
| Q3 24 | — | $362.2M | ||
| Q2 24 | — | $377.1M | ||
| Q1 24 | — | $439.1M |
| Q4 25 | $1.2B | $726.2M | ||
| Q3 25 | $917.3M | $739.3M | ||
| Q2 25 | $822.4M | $888.6M | ||
| Q1 25 | $765.2M | $900.0M | ||
| Q4 24 | $732.8M | $943.5M | ||
| Q3 24 | $577.2M | $991.0M | ||
| Q2 24 | $516.7M | $967.5M | ||
| Q1 24 | $464.0M | $967.5M |
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.2B | $1.7B | ||
| Q1 25 | $1.1B | $1.7B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $976.9M | $1.8B | ||
| Q2 24 | $914.1M | $1.8B | ||
| Q1 24 | $855.1M | $1.8B |
| Q4 25 | — | 0.63× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.45× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $73.7M |
| Free Cash FlowOCF − Capex | — | $51.4M |
| FCF MarginFCF / Revenue | — | 16.0% |
| Capex IntensityCapex / Revenue | — | 6.9% |
| Cash ConversionOCF / Net Profit | -0.18× | 5.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $82.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $73.7M | ||
| Q3 25 | $74.3M | $43.9M | ||
| Q2 25 | $64.0M | $32.7M | ||
| Q1 25 | $20.3M | $2.1M | ||
| Q4 24 | $40.4M | $78.5M | ||
| Q3 24 | $63.2M | $47.0M | ||
| Q2 24 | $25.0M | $83.4M | ||
| Q1 24 | $29.1M | $9.6M |
| Q4 25 | — | $51.4M | ||
| Q3 25 | $73.9M | $25.9M | ||
| Q2 25 | — | $18.8M | ||
| Q1 25 | — | $-13.5M | ||
| Q4 24 | — | $60.2M | ||
| Q3 24 | $63.2M | $31.6M | ||
| Q2 24 | — | $63.6M | ||
| Q1 24 | — | $-17.3M |
| Q4 25 | — | 16.0% | ||
| Q3 25 | 26.5% | 9.9% | ||
| Q2 25 | — | 6.0% | ||
| Q1 25 | — | -4.7% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | 25.2% | 10.6% | ||
| Q2 24 | — | 19.2% | ||
| Q1 24 | — | -5.5% |
| Q4 25 | — | 6.9% | ||
| Q3 25 | 0.1% | 6.9% | ||
| Q2 25 | — | 4.5% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 6.4% | ||
| Q3 24 | 0.0% | 5.2% | ||
| Q2 24 | — | 6.0% | ||
| Q1 24 | — | 8.6% |
| Q4 25 | -0.18× | 5.31× | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | 3.56× | ||
| Q1 25 | 1.07× | 0.12× | ||
| Q4 24 | 0.28× | 4.44× | ||
| Q3 24 | 1.93× | 2.61× | ||
| Q2 24 | 0.75× | 3.39× | ||
| Q1 24 | 1.76× | 0.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
